IVONESCIMAB MONOTHERAPY DEMONSTRATES STATISTICALLY SIGNIFICANT OVERALL SURVIVAL BENEFIT COMPARED TO PEMBROLIZUMAB MONOTHERAPY IN PD-L1-POSITIVE ADVANCED NSCLC IN HARMONI-2 STUDY CONDUCTED BY AKESO IN CHINA

Reuters · 3d ago

Please log in to view news